We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+2.62%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.87B
AUM Growth
-$718M
Cap. Flow
-$858M
Cap. Flow %
-45.75%
Top 10 Hldgs %
41.84%
Holding
112
New
12
Increased
13
Reduced
41
Closed
27

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$30.8M
2
XENT
Intersect ENT, Inc
XENT
+$26.9M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$19.7M
4
PDCO
Patterson Companies, Inc.
PDCO
+$17.7M
5
MCK icon
McKesson
MCK
+$13.1M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$49.3M
2
ELV icon
Elevance Health
ELV
+$43.6M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$41.3M
4
DBVT
DBV Technologies
DBVT
+$36.8M
5
CNC icon
Centene
CNC
+$36.6M

Sector Composition

Rank Sector Weight
1 Healthcare 71.91%
2 Financials 1.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
51
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.99M 0.48%
933,103
– –
IVTY
52
DELISTED
Invuity, Inc
IVTY
$8.54M 0.46%
1,177,229
-513,269
-30% -$3.99M
SEM
53
DELISTED
Select Medical
SEM
$7.75M 0.41%
+936,597
New +$7.03M
ARNA
54
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.03M 0.38%
+416,729
New +$5.71M
ALIM
55
DELISTED
Alimera Sciences
ALIM
$6.63M 0.35%
317,970
-73,898
-19% -$1.58M
SIOX
56
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.55M 0.3%
29,898
-41,103
-58% -$7.2M
BHVN
57
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.42M 0.29%
+216,761
New +$4.99M
MYOV
58
DELISTED
Myovant Sciences Ltd.
MYOV
$4.69M 0.25%
400,685
-304,583
-43% -$3.77M
SRRA
59
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.09M 0.22%
87,393
-36,915
-30% -$1.88M
MNKD icon
60
MannKind Corp
MNKD
$1.25B
$3.81M 0.2%
+2,702,403
New +$3.48M
FOMX
61
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.79M 0.2%
817,435
– –
AKTX
62
Akari Therapeutics
AKTX
$19.3M
$3.77M 0.2%
1,023
-415
-29% -$3.28M
MYOK
63
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$3.67M 0.2%
279,752
-145,048
-34% -$1.91M
OPCH icon
64
Option Care Health
OPCH
$3.41B
$3.6M 0.19%
331,992
-160,815
-33% -$1.22M
AGRX
65
DELISTED
Agile Therapeutics
AGRX
$3.58M 0.19%
478
-8
-2% -$55.4K
JNCE
66
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.48M 0.19%
247,872
-220,995
-47% -$4.73M
ZVRA icon
67
Zevra Therapeutics
ZVRA
$755M
$2.82M 0.15%
44,038
-23,740
-35% -$1.56M
BCRX icon
68
CALL
BioCryst Pharmaceuticals
BCRX
$2.36B
$2.78M 0.15%
+500,000
New +$3.05M
ARLZ
69
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$2.22M 0.12%
1,644,583
– –
TARA icon
70
Protara Therapeutics
TARA
$230M
$1.87M 0.1%
30,622
-2,693
-8% -$151K
HIND
71
Vyome Holdings
HIND
$15.1M
– –
0
– –
RARX
72
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.55M 0.08%
82,593
-95,237
-54% -$2.15M
VYGR icon
73
Voyager Therapeutics
VYGR
$192M
$1.05M 0.06%
117,647
– –
EPIX
74
DELISTED
ESSA Pharma
EPIX
$779K 0.04%
70,812
-35,268
-33% -$1.15M
KA
75
DELISTED
Kineta, Inc. Common Stock
KA
$81K ﹤0.01%
+123
New +$87.5K
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2017 Portfolio in Review

As of Q2 2017, Deerfield Management held 112 positions worth $1.87B, down 28% from $2.59B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $858M in Q2 2017, closing 27 positions and reducing 41 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $32.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 71% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intersect ENT, Inc worth $33.2M.

  • Deerfield Management's largest Q2 2017 buy was Intersect ENT, Inc: 1,189,577 shares worth $33.2M.
  • Deerfield Management added most to Glaukos in Q2 2017, an estimated $30.8M increase.
  • Deerfield Management's biggest Q2 2017 reduction was Blueprint Medicines, cutting an estimated $49.3M.
  • Deerfield Management fully exited Vanda Pharmaceuticals in Q2 2017, selling an estimated $32.2M.
  • Deerfield Management's ten largest holdings make up 42% of its $1.87B portfolio in Q2 2017.
  • Deerfield Management opened 12 new positions and closed 27 in Q2 2017.
  • Deerfield Management's portfolio value fell 28% quarter-over-quarter to $1.87B.

Based on Deerfield Management's 13F filing for Q2 2017, filed 14 Aug 2017.